Trial · NCT02418949
Altering Activation Patterns Post-stroke
NCT02418949, Not applicable, Completed, Shirley Ryan AbilityLab; results first posted 2021-07-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Altering Activation Patterns Post-stroke. Trials, record NCT02418949. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02418949
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Altering Activation Patterns Post-stroke
- NCT number
- NCT02418949
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 96 participants, actual
- Lead sponsor
- Shirley Ryan AbilityLab
- Conditions
- Stroke, Muscle Spasticity, Hemiparesis
- Interventions
- Cyproheptadine, Placebo for Cyproheptadine, Active Movement Practice (AMP), Passive Cyclical Stretching
- First posted
- 2015-04-17
- Last updated
- 2026-03-31
- Results first posted
- 2021-07-13
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) | baseline and 9 weeks (immediately post intervention) | GWMFT is a clinical outcome measure comprised of 15 timed tasks focusing on upper extremity function. Maximum allowable time per task is 120 seconds. |
| Secondary | Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC) | baseline and 9 weeks (immediately post intervention) | Following a maximum voluntary contraction (MVC) -- Time (s) required for muscle electromyographic (EMG) signals to reduce to within 3 SD of pre-MVC EMG activity. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) | baseline and 9 weeks (immediately post intervention) | Seconds | MEAN | |
| SECONDARY | Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC) | baseline and 9 weeks (immediately post intervention) | Seconds | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) | Cyproheptadine + AMP | -3.66 | 95% Confidence Interval -7.95 to 0.63 | Seconds | |
| Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) | Placebo for Cyproheptadine + Stretching | -0.51 | 95% Confidence Interval -3.62 to 2.60 | Seconds | |
| Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) | Cyproheptadine + Stretching | -4.00 | 95% Confidence Interval -7.72 to -0.28 | Seconds | |
| Change in Mean Completion Time for Graded Wolf Motor Function Test (GWMFT) | Placebo for Cyproheptadine + AMP | -3.89 | 95% Confidence Interval -8.65 to 0.88 | Seconds | |
| Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC) | Cyproheptadine + AMP | -1.66 | 95% Confidence Interval -2.79 to 0.54 | Seconds | |
| Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC) | Placebo for Cyproheptadine + Stretching | -0.96 | 95% Confidence Interval -3.20 to 1.28 | Seconds | |
| Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC) | Cyproheptadine + Stretching | -1.06 | 95% Confidence Interval -3.19 to 1.07 | Seconds | |
| Change in Grip Relaxation Time (Following a Maximum Voluntary Contraction (MVC) | Placebo for Cyproheptadine + AMP | -2.65 | 95% Confidence Interval -4.70 to -0.59 | Seconds |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cyproheptadine + AMP | 23 | |
| Overall Study | STARTED | Placebo for Cyproheptadine + Stretching | 22 | |
| Overall Study | STARTED | Cyproheptadine + Stretching | 26 | |
| Overall Study | STARTED | Placebo for Cyproheptadine + AMP | 25 | |
| Overall Study | COMPLETED | Cyproheptadine + AMP | 20 | |
| Overall Study | COMPLETED | Placebo for Cyproheptadine + Stretching | 21 | |
| Overall Study | COMPLETED | Cyproheptadine + Stretching | 23 | |
| Overall Study | COMPLETED | Placebo for Cyproheptadine + AMP | 24 | |
| Overall Study | NOT COMPLETED | Cyproheptadine + AMP | 3 | |
| Overall Study | NOT COMPLETED | Placebo for Cyproheptadine + Stretching | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events68
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry Mouth | General disorders | Cyproheptadine + AMP | 9 | 23 | 9 |
| other | Dry Mouth | General disorders | Placebo for Cyproheptadine + Stretching | 9 | 22 | 9 |
| other | Dry Mouth | General disorders | Cyproheptadine + Stretching | 11 | 26 | 11 |
| other | Dry Mouth | General disorders | Placebo for Cyproheptadine + AMP | 9 | 25 | 9 |
| other | Low Energy | General disorders | Cyproheptadine + AMP | 10 | 23 | 10 |
| other | Low Energy | General disorders | Placebo for Cyproheptadine + Stretching | 7 | 22 | 7 |
| other | Low Energy | General disorders | Cyproheptadine + Stretching | 12 | 26 | 12 |
| other | Low Energy | General disorders | Placebo for Cyproheptadine + AMP | 4 | 25 | 4 |
| other | Weight Gain | Metabolism and nutrition disorders | Cyproheptadine + AMP | 7 | 23 | 7 |
| other | Weight Gain | Metabolism and nutrition disorders | Placebo for Cyproheptadine + Stretching | 6 | 22 | 6 |
1 to 10 of 68Source ClinicalTrials.gov
See all 68 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cyproheptadine + AMP | 0 | 23 |
| Total, all-cause mortality | Placebo for Cyproheptadine + Stretching | 0 | 22 |
| Total, all-cause mortality | Cyproheptadine + Stretching | 0 | 26 |
| Total, all-cause mortality | Placebo for Cyproheptadine + AMP | 0 | 25 |
| Total, other adverse events | Cyproheptadine + AMP | 19 | 23 |
| Total, other adverse events | Placebo for Cyproheptadine + Stretching | 15 | 22 |
| Total, other adverse events | Cyproheptadine + Stretching | 18 | 26 |
| Total, other adverse events | Placebo for Cyproheptadine + AMP | 21 | 25 |
| Total, serious adverse events | Cyproheptadine + AMP | 2 | 23 |
| Total, serious adverse events | Placebo for Cyproheptadine + Stretching | 2 | 22 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers5
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01HD075813 | Altering Activation Patterns in the Distal Upper Extremity After Stroke | ROTH, ELLIOT J. | REHABILITATION INSTITUTE OF CHICAGO D/B/A SHIRLEY RYAN ABILITYLAB | EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT | 2014 to 2019 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02418949
GET https://conductscience.org/api/trials/v1/NCT02418949/events?page=2